Skip to main content
. 2023 Jul 11;14:1178489. doi: 10.3389/fphar.2023.1178489

FIGURE 4.

FIGURE 4

Collateral drug sensitivity was observed in capecitabine resistant Caco-2 cells. (A). Growth rate measurements at 24 h intervals for capecitabine-resistant Caco-2 replicate B, DMSO, and initial cells. (B). Scratch assay showing migration rates of capecitabine-resistant Caco-2 replicate B and DMSO control Caco-2 cell lines were measured based on the percentage of wound closure in 24, 36, 48, and 72 h intervals. (C). Dose response curve analysis for capecitabine-resistant Caco-2 replicate B exhibited collateral sensitivity to SN-38. (D). Dose response curve analysis in capecitabine-resistant Caco-2 replicate B showed collateral sensitivity to cetuximab. (E). Combination of capecitabine and SN-38 in capecitabine-resistant Caco-2 replicate B demonstrated collateral sensitivity. (F). Loewe score identified collateral sensitivity of capecitabine and SN-38 combination as an additive. (G). Cetuximab and capecitabine combination exhibited collateral sensitivity in capecitabine-resistant Caco-2 replicate B. (H). Synergy test performed using the Loewe score showed an additive effect of cetuximab and capecitabine combination for collateral sensitivity. Error bars represent SEM. *p < 0.5, **p < 0.01, ***p < 0.001 ****p < 0.0001.